We are three young guys with different backgrounds and areas of expertise, but with shared interests and ambitions. We have just started this journey and through our posts we aim to improve our Biotech knowledge and investment results, while providing you with our view on the stock. If you believe we overlooked something or should have used different assumptions, we really appreciate sharing this with us for further optimization.
Our composition consists of an investment banker turned venture capital analyst, a private banker with successful Biotech retail investing results, and a scientist with a Ph.D in molecular cell biology. By combining our expertise we aim to bring you valuable analyses of what we think are interesting companies to follow.
We understand that the Biotech companies we look at are risky bets. Hence, we only invest if we believe the science and previous study results form a good basis for future FDA approval. We do not actively trade but look at longer-term opportunities.
Following our first analysis on Citius Pharmaceuticals, which can be found on our reddit page, in our second report we look at 180 Life Sciences. In this analysis we see that the company shows great growth potential on the back of their early stage Duputren’s disease therapy.
In our analysis we will address the following topics:
• P2. Pipeline review
• P4. Trial evaluation
• P6. Management review
• P7. Target Addressable Market review
• P9. Discounted cashflow
• P10. Our opinion
We hope you find our analysis useful and look forward to your constructive feedback. As we actively work to improve, we appreciate it if you let us know your thoughts.
Finally, please follow us Stocktwits and Twitter (BiotechJourney) as there will be more analyses to come. Also, please let us know if there’s a particular stock you want us to perform an analysis on.
Click Below for the Due Diligence Report
This article was written by u/BiotechJourney